TISIDB

Summary
Symbol	TBC1D4
Name	TBC1 domain family, member 4
Aliases	KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location	13q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Note=Isoform 2 shows a cytoplasmic perinuclear localization in a myoblastic cell line in resting and insulin-stimulated cells.
Domain	PF11830 Domain of unknown function (DUF3350) PF00640 Phosphotyrosine interaction domain (PTB/PID) PF00566 Rab-GTPase-TBC domain
Function	May act as a GTPase-activating protein for RAB2A, RAB8A, RAB10 and RAB14. Isoform 2 promotes insulin-induced glucose transporter SLC2A4/GLUT4 translocation at the plasma membrane, thus increasing glucose uptake.

> Gene Ontology [ TOP ]
Biological Process	GO:0006906 vesicle fusion GO:0010639 negative regulation of organelle organization GO:0016050 vesicle organization GO:0031338 regulation of vesicle fusion GO:0031339 negative regulation of vesicle fusion GO:0032868 response to insulin GO:0032869 cellular response to insulin stimulus GO:0043434 response to peptide hormone GO:0044801 single-organism membrane fusion GO:0048284 organelle fusion GO:0051051 negative regulation of transport GO:0060627 regulation of vesicle-mediated transport GO:0061025 membrane fusion GO:0071375 cellular response to peptide hormone stimulus GO:0071417 cellular response to organonitrogen compound GO:0090174 organelle membrane fusion GO:0090630 activation of GTPase activity GO:1901652 response to peptide GO:1901653 cellular response to peptide
Molecular Function	GO:0005096 GTPase activator activity GO:0008047 enzyme activator activity GO:0017016 Ras GTPase binding GO:0017137 Rab GTPase binding GO:0030695 GTPase regulator activity GO:0031267 small GTPase binding GO:0051020 GTPase binding GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component	GO:0030659 cytoplasmic vesicle membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04919 Thyroid hormone signaling pathway
Reactome	R-HSA-199991: Membrane Trafficking R-HSA-1445148: Translocation of GLUT4 to the plasma membrane R-HSA-5653656: Vesicle-mediated transport

Summary
Symbol	TBC1D4
Name	TBC1 domain family, member 4
Aliases	KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location	13q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between TBC1D4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	TBC1D4
Name	TBC1 domain family, member 4
Aliases	KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location	13q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of TBC1D4 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	TBC1D4
Name	TBC1 domain family, member 4
Aliases	KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location	13q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of TBC1D4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.869	0.0409
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.691	0.676
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	1	0.418
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.033	0.91
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.134	0.951
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.245	0.93
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.162	0.693
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.056	0.975
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.249	0.902
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.534	0.642
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.017	0.522
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.225	0.0229

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of TBC1D4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	0	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	0	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	0	9.5	0.492
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	25	0	25	0.473
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	7.4	-2.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	7.7	1.4	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	TBC1D4
Name	TBC1 domain family, member 4
Aliases	KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location	13q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TBC1D4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	TBC1D4
Name	TBC1 domain family, member 4
Aliases	KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location	13q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TBC1D4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TBC1D4. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	TBC1D4
Name	TBC1 domain family, member 4
Aliases	KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location	13q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TBC1D4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	TBC1D4
Name	TBC1 domain family, member 4
Aliases	KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location	13q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of TBC1D4 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	TBC1D4
Name	TBC1 domain family, member 4
Aliases	KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location	13q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between TBC1D4 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	TBC1D4
Name	TBC1 domain family, member 4
Aliases	KIAA0603; AS160; DKFZp779C0666; Akt substrate of 160 kDa; NIDDM5; TBC (Tre-2, BUB2, CDC16) domain-containing ......
Chromosomal Location	13q22.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting TBC1D4 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse TBC1D4